Second malignancies following treatment in non-Hodgkin's lymphoma
- PMID: 8348069
- DOI: 10.3109/10428199309148531
Second malignancies following treatment in non-Hodgkin's lymphoma
Abstract
Second malignancies represent an important iatrogenic complication of the treatment of hematologic and other neoplasms. In this review we summarize the literature relating specifically to malignancies developing in the wake of treated non-Hodgkin's lymphoma (NHL). In these patients, the risk of myelodysplastic syndrome (MDS) and acute non lymphocytic leukemia (ANLL) is reported to be increased 10-105 fold over that of the general population. Factors in the development of MDS and ANLL include basic defects in cellular immunity in NHL patients as well as treatment with alkylating agents and low dose total body irradiation. Biologically these secondary MDS and ANLLs are characterized by specific cytogenetic abnormalities and results of treatment are poor. Currently bone marrow transplantation offers the only potential cure. There is no clear statistical evidence that solid tumors occur more frequently after NHL. However, bladder carcinoma, in cyclophosphamide treated patients, and lung cancer have been reported by some to occur with an increased incidence. Further investigation of the molecular events leading to the occurrence of second malignancies in NHL patients and the role played by oncogenes and tumor suppressor genes in this process is still needed.
Similar articles
-
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.J Clin Oncol. 2003 Mar 1;21(5):897-906. doi: 10.1200/JCO.2003.07.113. J Clin Oncol. 2003. PMID: 12610191 Review.
-
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).Leuk Lymphoma. 2001 Feb;40(5-6):499-509. doi: 10.3109/10428190109097649. Leuk Lymphoma. 2001. PMID: 11426523
-
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies.J Cancer Res Clin Oncol. 1998;124(3-4):207-14. doi: 10.1007/s004320050156. J Cancer Res Clin Oncol. 1998. PMID: 9619748 Review.
-
Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma.J Clin Oncol. 1996 Feb;14(2):565-71. doi: 10.1200/JCO.1996.14.2.565. J Clin Oncol. 1996. PMID: 8636772
-
Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 1994 Dec;12(12):2535-42. doi: 10.1200/JCO.1994.12.12.2535. J Clin Oncol. 1994. PMID: 7989927
Cited by
-
Second primary malignancies in multiple myeloma: A review.Blood Rev. 2021 Mar;46:100757. doi: 10.1016/j.blre.2020.100757. Epub 2020 Sep 6. Blood Rev. 2021. PMID: 32972803 Free PMC article. Review.
-
Incidental lymphoma in lymph node dissection for carcinoma in the abdominopelvic cavity: a single-institution experience.Virchows Arch. 2019 Sep;475(3):365-372. doi: 10.1007/s00428-019-02578-w. Epub 2019 May 2. Virchows Arch. 2019. PMID: 31044268
-
Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.J Clin Oncol. 2015 Oct 1;33(28):3096-104. doi: 10.1200/JCO.2014.60.2094. Epub 2015 Aug 3. J Clin Oncol. 2015. PMID: 26240221 Free PMC article.
-
Second malignancies in patients with primary central nervous system lymphoma.Neuro Oncol. 2015 Jan;17(1):129-35. doi: 10.1093/neuonc/nou105. Epub 2014 Jun 19. Neuro Oncol. 2015. PMID: 24948826 Free PMC article.
-
Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report.Case Rep Oncol. 2012 Jan;5(1):148-53. doi: 10.1159/000338040. Epub 2012 Mar 27. Case Rep Oncol. 2012. PMID: 22666204 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
